Therapeutical antibodies

• daratumumab
  2 May 2016

  WP
  Daratumumab (Darzalex) is an anti-cancer drug. It binds to CD38.
  Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.
  Clinical trials
  multiple myeloma

• necitumumab
  15 April 2016

  WP
  Necitumumab (proposed INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR).
  The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).

• ensituximab
  14 April 2016

  WP
  Ensituximab is designed against the mucin epitope NPC-1C in pancreatic and colon cancer.
  Ensituximab is a chimeric monoclonal antibody used in the treatment of cancers. Ensituximab was developed by Neogenix Oncology, Inc.
  Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) without contributing significant toxicity, according to findings from a (...)

• atezolizumab
  16 March 2016

  WP
  Definition: Atezolizumab (also known as MPDL3280A) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1). It is currently in clinical trials as an immunotherapy for several types of solid tumors.
  Atezolizumab blocks the interaction of PD-L1 with PD-1 and B7.1. PD-L1 can be highly expressed on certain tumors, which is thought to be a mechanism that leads to reduced activation of immune cells (cytotoxic T-cells (...)

• pembrolizumab
  15 March 2016

  MK-3475, lambrolizumab, trade name "Keytruda" WP
  Pembrolizumab is a humanized antibody used in cancer immunotherapy. It targets the programmed cell death 1 (PD-1) receptor. The drug was initially used in treating metastatic melanoma.
  On September 4, 2014 the US Food and Drug Administration (FDA) approved pembrolizumab under the FDA Fast Track Development Program.
  It is approved for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in (...)

• ramucirumab
  15 March 2016

  WP
  Ramucirumab (IMC-1121B, trade name Cyramza) is directed against the vascular endothelial growth factor receptor 2 (VEGFR2).
  By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis.
  It is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. (...)

• nivolumab
  13 July 2014

  Opdivo
  WP
  Nivolumab is an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.
  Nivolumab, a drug in clinical trials also known as BMS-936558 or MDX1106, is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer.
  Nivolumab acts by blocking a negative regulator of T-cell activation and response, thus allowing the immune system to attack the tumor. This is an example of immune (...)

• blinatumomab
  13 July 2014

  WP
  Blinatumomab (MT103) is a anti-CD19 drug that has anti-cancer properties. It belongs to a new class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells.
  Blinatumomab specifically targets the CD19 antigen present on B cells.
  The drug was developed by a German-American company Micromet, Inc. in cooperation with Lonza.
  Use
  refractory acute lymphoblastic leukemia (...)

• lambrolizumab
  3 June 2013

  MK-3475 WP
  Lambrolizumab (also known as MK-3475) is a drug in development by Merck that targets the PD-1 receptor. The drug is intended for use in treating metastatic melanoma.

• pertuzumab
  12 December 2012

  PERJETA ™ WKP
  Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody. it is the first of its class in a line of agents called "HER dimerization inhibitors".
  By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.
  Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer on June 8, 2012.
  Pertuzumab was developed at Genentech and is now owned by (...)

0 | 10 | 20 | 30 | 40